TRAM1L1: A Potential Drug Target for Cancer and Neurodegenerative Diseases

Target Name: TRAM1L1

NCBI ID: G133022

TRAM1L1

Other Name(s): MGC26568 | translocation associated membrane protein 1 like 1 | Translocating chain-associated membrane protein 1-like 1 | TR1L1_HUMAN | Translocation associated membrane protein 1 like 1

TRAM1L1: A Potential Drug Target for Cancer and Neurodegenerative Diseases

TRAM1L1 (MGC26568), a protein that belongs to the TRAM family, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to study and develop new treatments.

TRAM1L1 is a protein that is expressed in many different tissues throughout the body, including the brain, spinal cord, heart, kidneys, and intestines. It is a key regulator of the microglial cells, which are a type of immune cell that play a crucial role in fighting off infections and diseases. Mammalian genital tracts also express TRAM1L1.

TRAM1L1's unique structure is what makes it an attractive target for researchers. It has four known functions, including regulating the migration of immune cells, promoting neurogenesis, regulating inflammation, and modulating cell survival. Its structure allows it to interact with various molecules, including cytokines , growth factors, and chemokines, which are involved in the regulation of immune system and neural cells.

One of TRAM1L1's most promising functions is its role in cancer. Cancer is a disease that affects many different cells in the body, and it is the leading cause of death in the developed world. Many studies have suggested that TRAM1L1 may be involved in the development and progression of cancer. For example, TRAM1L1 has been shown to promote the growth and survival of cancer cells, and it has also been shown to inhibit the death of cancer cells.

TRAM1L1 has also been shown to be involved in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells, and they are some of the most common causes of dementia and other cognitive impairments. TRAM1L1 has has been shown to regulate the migration of immune cells to the brain, which may contribute to the development and progression of neurodegenerative diseases.

TRAM1L1 has also been shown to be involved in autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. These conditions are characterized by the immune system attacking the body's own tissues, and they can cause significant pain and disability. TRAM1L1 has been shown to regulate the activity of immune cells, which may contribute to the development and progression of autoimmune disorders.

In addition to its potential functions in cancer, neurodegenerative diseases, and autoimmune disorders, TRAM1L1 has also been shown to have potential as a drug target. Several studies have shown that TRAM1L1 can be targeted by small molecules, including inhibitors of tyrosine kinase, a type of enzyme that regulates the signaling of many different molecules. These inhibitors have been shown to have potential as a treatment for cancer, neurodegenerative diseases, and autoimmune disorders.

Overall, TRAM1L1 is a protein that has a unique structure and function that makes it an attractive target for researchers to study and develop new treatments. Its potential as a drug target and biomarker for cancer, neurodegenerative diseases, and autoimmune disorders makes it an important area of research to explore further. Further studies are needed to fully understand TRAM1L1's role in these conditions and to develop effective treatments.

Protein Name: Translocation Associated Membrane Protein 1 Like 1

Functions: Stimulatory or required for the translocation of secretory proteins across the ER membrane

The "TRAM1L1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAM1L1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets